Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-PN serum collection for assay validation
NCT07205289Phase 1Recruiting
- Sponsor
- GPN Vaccines
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Gamma-PN in pneumococcal disease, sponsored by GPN Vaccines. Primary endpoint: Opsonophagocytic Activity at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
Gamma-PN
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07205289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205289.